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Summary
What is already known on this topic?
Evidence shows that pharmacist-provided medication management can
improve chronic disease outcomes; however, pharmacists are not consist-
ently considered integral members of health care teams.
What is added by this report?
It provides an example of how collaboration among state public health,
clinical, and academic partners can catalyze expansion of models of care
that include pharmacists and that inclusion of pharmacists on care teams
has the potential to improve chronic disease outcomes.
What are the implications for public health practice?
Findings can provide guidance to public health, clinical, and academic
partners in their efforts to expand care models that include pharmacists,
to help improve chronic disease outcomes.
Abstract
Introduction
Pharmacists  are underused in the care of  chronic disease.  The
primary objectives of this project were to 1) describe the factors
that  influence  initiation  of  and  sustainability  for  pharmacist-
provided medication therapy management (MTM) in federally
qualified health centers (FQHCs), with secondary objectives to re-
port the number of patients receiving MTM by a pharmacist who
achieve 2) hemoglobin A1c (HbA1c) control (≤9%) and 3) blood
pressure control (<140/90 mm Hg).
Methods
We evaluated MTM provided by pharmacists  in 10 FQHCs in
Ohio through qualitative thematic analysis of semi-structured in-
terviews with pharmacists and FQHC leadership and aggregate re-
porting of clinical markers.
Results
Facilitators of MTM included relationship building with clini-
cians, staff, and patients; regular verbal or electronic communica-
tion with care team members; and alignment with quality goals.
Common MTM model elements included MTM provided distinct
from dispensing medications, clinician referrals, and electronic
health record access. Financial compensation strategies were inad-
equate and varied; they included 340B revenue, incident-to billing,
grants, and shared positions with academic institutions. Of 1,692
enrolled patients, 60% (n = 693 of 1,153) achieved HbA1c ≤9%,
and 79% (n = 758 of 959) achieved blood pressure <140/90 mm
Hg.
Conclusion
Through this statewide collaborative, access for patients in FQHCs
to MTM by pharmacists increased. The factors we identified that
facilitate MTM practice models can be used to enhance the mod-
els to achieve clinical goals. Collaboration among clinic staff and
community partners  can improve models  of  care  and improve
chronic disease outcomes.
Introduction
Although well positioned to fill gaps in health care, pharmacists
have long been underused (1,2).  This  is  especially relevant  in
chronic disease management despite evidence that demonstrates
pharmacists’ success in improving outcomes through collaborat-
ive care and medication therapy management (MTM) (1–6). MTM
involves a multifaceted approach of reviewing medications, identi-
fying and remedying medication-related problems, providing dis-
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ease state management and self-management education, address-
ing  medication  adherence  issues,  and  considering  preventive
health strategies to optimize medication-related health (3,4,7,8).
An MTM service includes a comprehensive medication review to
ensure that the patient’s medication-related needs have been met
and all of their medications are appropriate, effective, safe, and
convenient. At the end of the visit, a care plan is developed and
shared with the patient and the primary care provider to resolve
and prevent any drug therapy problems by eliminating unneces-
sary medications,  initiating appropriate medications,  adjusting
dosage regimens, addressing adverse reactions, and increasing the
patient’s willingness and ability to adhere to the medication regi-
men (9,10). Through MTM, pharmacists play an important role in
addressing health care disparities in underserved areas (11–14).
Developments including passage of the Patient Protection and Af-
fordable Care Act (15), subsequent expansion of Medicaid, and
the establishment of federally qualified health centers (FQHCs)
have created more opportunities for pharmacists to provide care in
community-based settings. Integration of MTM remains limited in
many community-based settings due to lack of reimbursement,
medical provider buy-in, time, and resources (16,17). Addition-
ally, evidence is sparse with regard to outcomes in FQHCs and
factors that facilitate initiation, continuation, and sustainability of
care provided by pharmacists in FQHCs (17,18).
The Ohio Department of Health (ODH), Ohio Pharmacists Associ-
ation (OPA), and Ohio Association of Community Health Centers
(OACHC) collaborated with colleges of pharmacy in Ohio on a 5-
year, 2-phase project to address these gaps and opportunities. This
project involved developing a statewide learning community and
advisory board, tracking aggregate outcomes for patients receiv-
ing care from pharmacists, and qualitatively evaluating processes
surrounding pharmacist-provided MTM. The primary objectives
of this project were to 1) describe factors that influence initiation
of and sustainability for pharmacist-provided MTM in FQHCs,
and 2) report the number of patients receiving MTM by a phar-
macist who achieved hemoglobin A1c (HbA1c) control (≤9%) and
blood pressure control (<140/90 mm Hg).
Methods
This was a multi-site, prospective project approved by the institu-
tional review boards of The Ohio State University and the Ohio
Department of Health. A multidisciplinary consortium was cre-
ated to oversee the project. The consortium set a mission to ex-
pand team-based care involving pharmacists to prevent chronic
disease; disseminate outcomes to support successful models of
care; and collaborate across private, public, and academic entities
to promote statewide advancement in patient access to pharmacist
care. Members of the consortium included representatives from
the ODH, the OPA, the OACHC, all 7 colleges of pharmacy in
Ohio, the state’s Medicare quality improvement organization, and
pharmacists providing care to patients in FQHCs. The consortium
met quarterly to guide project activities, review goals and plans for
disseminating outcomes,  and share  updates  and best  practices
among the FQHC pharmacists related to practice models and care
strategies. The project used qualitative research methods and de-
scriptive statistics to report on objectives.
The first project phase (Phase 1) was initiated in March 2014 and
concluded in December 2016 and involved 3 FQHCs with well-es-
tablished models for pharmacists to provide MTM to patients. The
processes for recruitment, quantitative data reporting, and analysis
for this first phase were published previously (19). Patients were
recruited at each FQHC from reports created with each site’s elec-
tronic health record (EHR). Patients were included if they were
aged 18 to 75 years; had a diagnosis of hypertension, diabetes, or
both, with diagnosis occurring at least 1 year prior; were seen for a
medical visit(s) at least once in the last year; and had a most re-
cent HbA1c >9% and/or a most recent systolic blood pressure ≥140
mm Hg or diastolic blood pressure ≥90 mm Hg. We assessed how
well patients had control of their diabetes (good control, HbA1c
<7% to poor control, HbA1c >9%) and whether patients had con-
trolled (<140/90 mm Hg) or uncontrolled (≥140/90 mm Hg) hy-
pertension. Visit lengths and structures varied with the pharmacist
providers based on individual patient needs and clinic structures
among the 10 FQHCs involved in the project. Follow-up data were
gathered from EHRs in each FQHC site and reported centrally to
the Ohio Department of Health for analysis. These metrics were
based on Uniform Data System clinical measures defined by the
Health Resources and Services Administration (HRSA) and re-
quired for reporting by FQHCs (20). Patients were excluded if
they were pregnant, diagnosed with end stage renal disease, or had
received a pharmacist visit at the site within 1 year before enroll-
ment.
The second phase (Phase 2) of this project was initiated in Janu-
ary 2016.  Investigators recruited 2 additional  cohorts  of  phar-
macists. These next 2 cohorts (4 FQHCs in the first and 3 in the fi-
nal) included pharmacists with new or emerging opportunities to
establish pharmacist-provided MTM in FQHCs. First and second
phase sites (10 sites in total) provided MTM according to their in-
dividual clinic policies, procedures, and workflow. Inclusion and
exclusion criteria as well as quantitative data reporting and analys-
is were the same for the first and second phases of the project (19).
All  10  sites  continued  to  enroll  patients  from their  start  date
through December 31, 2017; data reporting concluded on June 30,
2018.
To understand facilitators and barriers to implementing MTM in
an FQHC setting, semi-structured interviews were conducted with
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both clinical pharmacists and nonpharmacist clinic leaders (eg,
medical directors, chief executives) recruited from FQHCs taking
part in this project. The 3 sites from Phase 1 and 5 of the 7 sites
from Phase 2 participated in the qualitative interviews; however,
due to site staff turnover and resulting incomplete information,
qualitative data from one Phase 2 site was eliminated from themat-
ic analysis, leaving 7 total sites involved in the qualitative analys-
is. Comparable qualitative data were not collected from sites in the
final cohort, because these sites were still in the process of initiat-
ing MTM services and could not contribute comparable data.
A single investigator identified a clinical pharmacist to be inter-
viewed at each FQHC. Clinical pharmacists then identified non-
pharmacist  clinic  leaders  in  their  affiliated FQHC to be inter-
viewed in an effort to gather more than one perspective at each
FQHC and capture the nuances and complexity of MTM imple-
mentation at each site.
Interview protocols were developed by 3 investigators with input
from ODH epidemiology and evaluation staff. A set of interview
protocols was developed for each clinical pharmacist to capture
perspectives close to the beginning of each project phase and 6 to
12 months later. A separate protocol, drawn from a subset of ques-
tions from the clinical pharmacy protocol, was developed to cap-
ture the perspectives of nonpharmacist clinic leaders. Protocols
aimed to gather information about each site’s approach to imple-
menting MTM: rationale for implementing the service; financial
supports used; patient identification and referral processes; staff-
ing; elements of the MTM model of care; and key facilitators, bar-
riers, and lessons learned, as well as the future sustainability of
MTM at each site and advice for others contemplating MTM im-
plementation.
Two investigators conducted telephone interviews with clinical
pharmacists at each of the 3 Phase 1 sites between July and Au-
gust 2015 and again in January 2016. Nonpharmacist clinic lead-
ers from these sites were interviewed in January and February
2016. A similar series of interviews was conducted with 4 Phase 2
sites by the same 2 investigators in July 2016 and again in July or
August 2017. All interviewees consented to have their interviews
recorded and were provided with their interview summary to re-
view for completeness and accuracy. Corrections or additions sup-
plied by interviewees were incorporated into the final summaries.
After finalizing all interview summaries (n = 20 interviews, n = 14
unique interviewees) across cohorts, 2 investigators conducted an
inductive, cross-case thematic analysis (19) using the qualitative
data analysis software NVivo11 (QSR International). Informed by
analysis techniques described in Patton (21) and Charmaz (22) and
to identify emergent themes, 2 investigators identified and dis-
cussed broad common themes and broke those themes down fur-
ther to more nuanced themes. Throughout this process, investigat-
ors resolved any differences that arose via consensus. The themes
were further vetted for cohesiveness and validity by 2 additional
investigators with training and experience in clinical pharmacy
and  MTM.  Significance  throughout  qualitative  analysis  was
defined by the study team as at least 4 of the 7 sites reporting an
element or theme. Quotations or excerpts from interview summar-
ies and recordings were de-identified to protect the confidentiality
of the interviewees and the FQHCs.
Results
Seven pharmacists (2 male, 5 female) and 7 nonpharmacist clinic
leaders (2 male, 5 female) from 7 FQHC sites were interviewed.
Information gathered during these interviews was categorized into
3 key areas related to MTM models of care in FQHCs: common
elements (Table 1), strategies for financial compensation (Table
2), and facilitators to initiation, continuation, and expansion (Ta-
ble 3).
Elements of clinic structure, workflow, and patient care processes
common to all sites providing MTM in FQHCs were pharmacists
providing MTM services billed through Medicare Part D–integ-
rated platforms (eg, Mirixa [Outcomes Incorporated], Outcomes-
MTM [Cardinal  Health]),  at  least  partial  pharmacist  access  to
EHRs, a care team minimally inclusive of a medical provider and
a pharmacist, and referral of patients to pharmacists by a medical
provider. With regard to clinic operations, a notable commonality
described among all MTM models was patient visits with phar-
macists separate from dispensing functions (Table 1).
Strategies for financial compensation for MTM also demonstrated
commonalities with all sites engaging in billing through MTM
platforms and every FQHC reporting involvement in a 340B drug
pricing program. Other strategies for financial compensation were
mixed and included clinic or pharmacy grants, collaboration or
shared funding with a college of pharmacy, and billing with evalu-
ation  and  management  medical  codes  either  as  incident-to  or
through shared medical visits (Table 2).
Facilitators were organized based on whether they were related to
MTM initiation or continuation and expansion (Table 3). In addi-
tion to the top facilitators described in Table 3, the need for sus-
tainable compensation for pharmacists providing MTM emerged
as another significant  theme among pharmacists  and nonphar-
macist leaders. The lack of adequate levels and modalities of reim-
bursement for care was described as a major barrier to initiation
and expansion of MTM. Interviews across all sites mentioned the
importance of recognition of pharmacists as providers and the
need for appropriate financial compensation for care provided by
pharmacists. For example, one clinic leader shared:
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Recognizing pharmacists as providers at the federal level would
help with reimbursement for services. If the provider status of phar-
macists is ever approved, they will be able to obtain adequate reim-
bursement for Medicaid and Medicare, can bill  under the phar-
macists’ name, and will be properly paid for their time and effort.
Depending on the degree to which this actually happens and how
many insurance providers will accept the change in status, [phar-
macists] could add more clinical positions and not rely solely on
medication dispensing. If this were approved, [pharmacies] would
hire  more  pharmacists,  serve  many  more  patients,  and  could
provide clinical services at locations where they don’t have a dis-
pensing component.
Other themes emerged but did not reach significance, including
workflow and clinical infrastructure considerations and staff edu-
cation. More specifically, a few sites mentioned the importance of
clinicians directly referring patients to pharmacists, availability of
private rooms for pharmacist and patient meetings, clinicians’ pri-
or experience collaborating with pharmacists on patient care, and
pharmacists with past experience providing comprehensive MTM
as being important facilitators of MTM initiation. Educating non-
clinicians and other clinic staff on MTM (what it entails, benefits
of) was mentioned by a few sites as important to obtaining buy-in
and support for MTM, along with educating patients and clini-
cians to improve understanding and participation.
Between March 2014 and December 2017, 1,692 patients were en-
rolled in this study at the 10 FQHCs in all phases of the project;
1,153 of these patients were enrolled with uncontrolled diabetes,
and 959 of these patients were enrolled with uncontrolled hyper-
tension. At final data collection ending on June 30, 2018, approx-
imately  60% (n  = 693)  of  patients  with  uncontrolled  diabetes
achieved an HbA1c ≤9%, 20.6% (n = 238) between 8% and 9%,
20.2% (n = 233) between 7% and <8%, and 19.3% (n = 222) <7%
(Figure 1). Of those with hypertension, 79% (n = 758) achieved a
blood pressure that was in range at <140/90 mm Hg (Figure 2).
Figure  1.  Aggregate  achievement  of  HbA1c  goals  of  patients  enrolled  in
medication  therapy  management  (MTM)  services  at  10  Ohio  federally
qualified health centers from March 2014 through June 2018. Abbreviation:
HbA1c, hemoglobin A1c.
Figure 2. Aggregate achievement of blood pressure (BP) goals of patients
enrolled in medication therapy management services at 10 Ohio federally
qualified health centers from March 2014 through June 2018.
Discussion
Semi-structured interviews with pharmacists and FQHC leader-
ship identified common elements of MTM workflow among sites
and key facilitators to initiation, continuation, and expansion of
these services. Patients with previously uncontrolled diabetes and
blood pressure displayed aggregate achievement of HbA1c  and
blood pressure goals following visits with pharmacists.
The degree of clinical goal achievement in this project was com-
parable to results reported by the Patient Safety and Clinical Phar-
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macy Services  Collaborative  (PSPC),  a  national  initiative  de-
signed by HRSA in 2008 to enhance medication use in safety-net
organizations, including FQHCs. In 2012, PSPC reported achieve-
ment of goals, with 35% of PSPC sites attaining desired HbA1c
levels  and 43% of  PSPC sites  reporting meeting hypertension
goals. In the Ohio project, 60.1% of patients achieved HbA1c goals
and 79.0% reported achievement of hypertension targets (23). The
Change Package initiative with PSPC provided implementation
steps and best practice tips from FQHCs with established phar-
macy services. The Change Package recommendations align with
themes that emerged in the Ohio MTM analysis. Similar facilitat-
ors  between  the  2  included  identifying  physician  champions,
providing EHR access for pharmacists, sharing outcomes from
pharmacy services with clinic leadership and clinicians, educating
clinicians on benefits of clinical pharmacy services,  and phar-
macists engaging in regular communication with clinicians and
care team members (18).
Investigations have demonstrated strategies to build successful
pharmacist-provided MTM in community-based settings, such as
FQHCs. Pestka et al (17) proposed a stepwise process for com-
munity pharmacies to integrate MTM into practice sites. With the
focus on traditional community pharmacies, their findings were
aimed mainly at the internal pharmacy staff and considerations for
changes within the pharmacies. In our qualitative analysis of phar-
macists in FQHCs, it is notable that many of the key facilitators to
initiation involved stakeholders external to the pharmacists and
pharmacy staff, such as clinicians, patients, and clinic leadership.
Snyder et al (16) evaluated 3 community-based models of care in-
cluding  an  independent  pharmacy,  a  chain  pharmacy,  and  an
FQHC practice model. Barriers to MTM in these settings included
reimbursement as well as lack of provider buy-in, time, resources,
and collaborative practice agreements (CPAs).  Facilitators  in-
cluded team-based care and collaboration with academic partners.
Jorgensen et al (24) conducted telephone interviews with phar-
macists, physicians, and nurse practitioners from 23 health care
teams that had integrated a new pharmacist role and identified 7
key themes describing the barriers and facilitators the teams exper-
ienced during pharmacist integration. The themes identified in
their study aligned and reinforced results described in this project,
including the importance of relationship-building, experience of
providers working with pharmacists, and the need for adequate re-
sources  and  funding.  Finally,  Fischer  et  al  (25)  conducted  a
mixed-methods cohort study in one FQHC with a pharmacy to ex-
amine  the  implementation  and impact  of  a  broad program in-
volving MTM. Interviews identified enabling factors to success
that align with our results, including data access, leadership sup-
port, staffing, and 340B funding.
 
Our findings correlate well with other pharmacist service–specific
literature, which confirms and expands the evidence base for phar-
macist-provided care in FQHCs. However, no previous study in-
volved the breadth and number of FQHCs and interview parti-
cipants as the Ohio project. Additionally, no previous study de-
scribed a state-specific learning community. The state-focused col-
laboration involving the OPA, all 7 colleges within the state, the
ODH, and OACHC facilitated a learning and practice advance-
ment consortium with shared payor opportunities as well as phar-
macy practice act considerations.
Strategies for financial compensation varied among the sites in-
volved in this statewide project. Sites identified that improvement
in compensation opportunities for pharmacists as providers of care
is needed and may be necessary for continued expansion of phar-
macy services in FQHCs. Murawski et al (26) evaluated practice
characteristics and reimbursement for pharmacists in certified col-
laborative clinical practice in New Mexico and North Carolina and
found, as we did, that despite integration and acceptance of phar-
macists providing care by patients and clinicians, reimbursement
challenges continued to limit expansion of the model.
Limitations
Individual pharmacists and FQHCs developed the workflow mod-
els that fit with their infrastructure, resources, and patient popula-
tions. Thus, these individual processes of care may have influ-
enced results by introducing unknown confounders because quant-
itative data was not analyzed at the individual FQHC site or pa-
tient level. Patient experience with the pharmacist-provided care
was not evaluated in this study and is an opportunity for future
evaluation. Transcripts from interviews conducted with first phase,
experienced sites as well as second phase, emerging sites were
compiled and analyzed as  one group of  data.  Data from phar-
macist and nonpharmacist interviewees were also analyzed in ag-
gregate and included 7 of the 10 pharmacy sites. An additional
confounder was that a few questions were developed and added
mid-study, based on information volunteered by some early inter-
viewees.  Themes that  arose from responses to those questions
were less likely to reach thematic significance. For example, ex-
pansive CPA legislation involving pharmacists and physicians
were passed in Ohio in 2016 while this project was in process. A
consistent theme or commonality in CPAs may have arisen if all
interviewees had been asked to discuss CPAs during all interview
phases.
Conclusion
Statewide collaboration among state public health, FQHCs, phar-
macists, and colleges can catalyze expansion of pharmacist mod-
els of care and improve chronic disease outcomes. Through this
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statewide collaborative, patients cared for in FQHCs had access to
pharmacist-provided MTM services  for  diabetes  and/or  blood
pressure management. Although this statewide public health col-
laboration model with pharmacy is transferable to other states, key
elements to patient care models and facilitators to success that
were identified can be applied at the clinic site level to build suc-
cessful MTM models of care in FQHCs. Pharmacists and other
health care providers and policy makers must continue to strive for
sustainable financial compensation to improve patient access to
pharmacist-provided MTM.
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Tables
Table 1. Common Elements to Medication Therapy Management Models of Care in 7 Ohio Federally Qualified Health Centers (FQHCs), March 2014–June 2018
Element 7 FQHCs 4–6 FQHCs
Clinic and pharmacy structure
MTM services provided onsite at FQHC ●
Pharmacy has at least partial clinical access to EHR ●
Collaborative Practice Agreement used ●
On-site pharmacy ●
FQHC owns pharmacy ●
Care team members
Medical provider (MD, NP, PA) ●
Pharmacist ●
Pharmacy resident(s) ●
Pharmacy student(s) ●
Patient identification
Medical provider referral ●
Referral through EHR ●
EHR data mining ●
Eligibility criteria
Uncontrolled chronic conditiona ●
Multiple medications (ie, polypharmacy) ●
Visit structure and content
Separate visit with a pharmacistb ●
MTM platform documentation and billingc ●
Communication (verbal or via EHR) with clinician ●
Medication assistance (ie, cost) ●
Abbreviations: EHR, electronic health record; MD, doctor of medicine; MTM, medication therapy management; NP, nurse practitioner; PA, physician assistant.
a Inclusion criteria required patients to have either uncontrolled hypertension (blood pressure >140/90 mm Hg) or uncontrolled type 2 diabetes (hemoglobin A1c
>9%).
b Two sites also conducted joint visits with a medical provider.
c Mirixa (Mirixa Corporation, Reston, Virginia) and/or OutcomesMTM (Cardinal Health, Dublin, Ohio).
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Table 2. Medication Therapy Management (MTM) Financial Compensation Strategies Implemented in 7 Ohio Federally Qualified Health Centers, March 2014–June
2018
Site
OutcomesMTM and/or Mirixa
Electronic MTM Platforms
Participation in 340B Drug
Pricing Program
Medical
Billinga
Portion of Pharmacist
Salary Supported by a
University
Clinic Budget
or Grants
Pharmacy Budget or
Grants
1 ● ●b ●c,d ● ●
2 ● ●b ● ●
3 ● ●e ●
4 ● ●c ●
5 ● ●b
6 ● ●c ● ●
7 ● ●c ● ● ●
a Billing through Evaluation and Management codes 99211–99215.
b Funds go to clinic, used to expand clinical pharmacy services, including MTM.
c Funds go to clinic, not allocated to any specific services.
d Billing through lower-level, incident-to code 99211.
e Funds go to clinic, used to support patient care generally. No information available about allocation of funds to MTM or other clinical pharmacy services.
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Table 3. Facilitators to Initiation, Continuation, and Expansion of Medication Therapy Management Models of Care in 7 Ohio Federally Qualified Health Centers,
March 2014–June 2018
Theme (No. of Sites Contributing to
Theme) Selected Representative Statements
Facilitators to Initiation
Identify or cultivate a champion in
administration, quality improvement
committee, or C-suite (n = 7)
The administrative team and the board of directors were all supportive of MTM from the beginning. The CEO is a
registered nurse with a strong clinical background and understood the need for MTM.
The CMO has a history of working with clinical pharmacists for most of her career. One of the primary preceptors (a
physician) had a BS in pharmacy as an undergraduate. The CEO of the clinic is also supportive of pharmacy being an
integral part of the clinic. The support is embedded within the culture. The clinic is extremely supportive of pharmacy.
Engage clinician champions (n = 7) The associate medical director indicated relying on pharmacists to help provide education and follow-up support to her
patients. This carries over into new clinician orientation where she talks about how helpful support from pharmacists has
been to her and her patients and encourages them to take advantage of on-site MTM services.
The clinical pharmacist reports that open communication with clinicians and finding clinician champions early on who are
supportive of a pharmacist’s role on the care team are important. Champions can be used as a sounding board and can
relay to other clinicians how pharmacists can complement their work with patients.
At first the clinical pharmacist worked exclusively with one NP who had some previous experience working with a
pharmacist. This NP became a champion and served as a model for other clinicians. The NP would identify 10 to 20 of
his patients with the greatest needs who had upcoming appointments and ask the clinical pharmacist to work with them.
Through this collaboration, they were able to capture data to show the benefit of MTM.
Ensure pharmacists have support to
conduct MTM outside of medication
dispensing (n = 7)
The CMO remarked that it is often difficult for a dispensing pharmacist to have time to conduct MTM. Having a clinical
pharmacist and resident, and sometimes students, who can conduct or help with MTM has been key.
The clinical pharmacists work alongside the medical providers and not in the dispensary.
Align the potential benefits of MTM with
FQHC quality care goals (patient
experience, health outcomes, clinical
quality measures) (n = 7)
From the start of MTM, administrators were excited about MTM because of the potential it held for improving patient
outcomes
Reimbursement was not as important to administrators as improving quality of patient care and, along with that, quality
measures.
MTM improves the quality of patient care . . . and helps them achieve their goals as a patient-centered medical home.
Educate clinicians on how pharmacists
can contribute to the care team (n = 4)
In the beginning, to help foster buy-in among clinicians, the clinical pharmacist held monthly 1-hour meetings to present
the project and to describe how the pharmacist planned to communicate with the clinicians about patient care.
Before implementation of MTM, the clinical pharmacist attended medical staff meetings. She introduced the program in
advance so that everyone was clear about what it offered and worked to establish relationships with clinicians in
advance.
The CEO noted that initially some clinicians and staff had a tough time grasping the idea of having a pharmacist on the
care team, so the clinical pharmacist started out providing some basic information to clinicians such as what MTM is and
how to use pharmacy services.
Facilitators to continuation and expansion
Collect data on patient outcomes/quality
of care; share with clinicians and
management (n = 7)
Collecting, tracking, and sharing outcome data with clinicians and management were very important. The clinical
pharmacist had a plan from the beginning as to how they were going to use the data to increase buy-in and support for
MTM. They track 3 types of data: physician perspectives, patient perspectives, and patient outcomes, for example,
hemoglobin A1C, blood pressure, and LDL cholesterol. Without this evidence they would not have support continued for
their efforts.
The CEO noted that once a practice is able to document positive patient outcomes and share those outcomes with
clinicians, they see the value of it. The clinical pharmacist produces a quarterly newsletter that includes a patient story.
The CEO finds this has been an effective communication strategy for clinicians and staff.
Show how clinical pharmacy services
benefit the care team (n = 7)
The associate medical director noted that having pharmacists on the care team really enhances the team: “[The
pharmacist's efforts] could serve as a text-book example of what team-based care looks like in a PCMH.”
The CEO remarked that physicians support MTM because the program allows them to do their job. They do not have
extensive time to speak with patients about medication adherence or to provide the lengthy conversations needed to
help patients who are confused, elderly, cannot read, or just cannot understand. Clinicians know if they hand these
Abbreviations: 340B, 340B drug pricing program; BS, bachelor of science; C-suite, top senior staff within an FQHC; CEO, chief executive officer; CMO, chief medical
officer; EHR, electronic health record; FQHC, federally qualified health center; LDL, low-density lipoprotein; MCOs, Medicaid-managed care organizations; MTM,
medication therapy management; NP, nurse practitioner; PCMH, patient-centered medical home.
(continued on next page)
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(continued)
Table 3. Facilitators to Initiation, Continuation, and Expansion of Medication Therapy Management Models of Care in 7 Ohio Federally Qualified Health Centers,
March 2014–June 2018
Theme (No. of Sites Contributing to
Theme) Selected Representative Statements
patients off to the pharmacist that it makes their day go more smoothly.
Seek and illuminate the financial
benefits of MTM to the clinic (n = 7)
The executive director and chief financial officer have always been supportive of pharmacy services, but as
reimbursement is starting to be tied to it (eg, quality of care, reduced hospital readmissions), there is a greater focus on
this type of service.
They also plan to continue having conversations with third-party payers (eg, MCOs) around direct reimbursement for
MTM.
Clinic management and physicians see the benefit of investing 340B revenue into clinical pharmacy services because it
improves patient outcomes.
There was no expectation from the FQHC that MTM should generate revenue to support the clinical pharmacist’s salary.
But as the project developed, he began to plan for ways to make MTM sustainable post grant. He wanted to be able to
show the project’s worth, and also to avoid having the position be a cost burden.
Communicate regularly with clinicians (in
person or via EHR) (n = 6)
The clinic workstation is shared by all of the clinicians, and the clinical pharmacist finds this helps facilitate collaboration
across staff and clinicians.
All pharmacists are also invited to attend the monthly clinician meeting. In the past, these meetings were only for
physicians and nurse practitioners. The pharmacists requested to be invited to attend those meetings as well. This allows
pharmacists a chance to interact with clinicians outside of the clinic and the opportunity to hear what they are hearing
from administration.
Now that the clinical pharmacist has access to the health center's EHR, they can document visit notes and
recommendations directly into the EHR as they meet with patients.
Show how MTM contributes to meeting
clinic goals (n = 6)
The associate medical director finds that providing MTM makes it easier for the clinic to reach its quality goals and make
improvements in quality measures, for example hemoglobin A1c levels for diabetes.
Focusing on quality measures was already a priority at this organization, so the MTM team worked to incorporate
improvement in these measures as a priority.
External factors such as quality measures certainly influence clinicians’ and administration’s willingness to take on MTM.
The clinical pharmacist expects they will have the data they need to demonstrate these improvements to providers and
administration.
Build relationships with clinicians (n = 5) Where the clinical pharmacist sees the greatest need for clinical pharmacy is in support of midlevel clinicians (eg, nurse
practitioners and physician assistants) and is working on building relationships with these clinicians.
Getting buy-in can be a challenge but is critical. The clinical pharmacist suggests that pharmacists work alongside
physicians as much as possible, spend time at the nurses’ station, stay in communication, and get to know the medical
assistants. Other care team members don’t necessarily know what pharmacists can do, so they need to be there to show
them what they can do. It is important to build these relationships and know that this might take time.
There is still more work to be done, however, to build support for MTM among clinicians. Some clinicians still don’t trust
the service, or they just get caught in their old routines and don’t think about how the pharmacist can help them. The
clinical pharmacist thinks that continuing to build relationships with each clinician, by helping answer their patient’s
questions, will help her build buy-in for working with a larger number of patients in a more in-depth manner.
Abbreviations: 340B, 340B drug pricing program; BS, bachelor of science; C-suite, top senior staff within an FQHC; CEO, chief executive officer; CMO, chief medical
officer; EHR, electronic health record; FQHC, federally qualified health center; LDL, low-density lipoprotein; MCOs, Medicaid-managed care organizations; MTM,
medication therapy management; NP, nurse practitioner; PCMH, patient-centered medical home.
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